Illumina, Inc. ILMN
We take great care to ensure that the data presented and summarized in this overview for ILLUMINA, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ILMN
View all-
Capital World Investors Los Angeles, CA20MShares$2.41 Billion0.27% of portfolio
-
Black Rock Inc. New York, NY18.1MShares$2.18 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.6MShares$1.77 Billion0.02% of portfolio
-
State Street Corp Boston, MA6MShares$724 Million0.02% of portfolio
-
Sessa Capital Im, L.P. New York, NY4.69MShares$566 Million10.94% of portfolio
-
Loomis Sayles & CO L P4.29MShares$517 Million0.5% of portfolio
-
Wcm Investment Management, LLC Laguna Beach, CA4.18MShares$505 Million0.9% of portfolio
-
Corvex Management LP New York, NY3.83MShares$462 Million14.76% of portfolio
-
Aqr Capital Management LLC Greenwich, CT3.4MShares$410 Million0.21% of portfolio
-
Geode Capital Management, LLC Boston, MA2.74MShares$331 Million0.02% of portfolio
Latest Institutional Activity in ILMN
Top Purchases
Top Sells
About ILMN
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Insider Transactions at ILMN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2025
|
Scott B. Ullem Director |
BUY
Grant, award, or other acquisition
|
Direct |
212
+2.41%
|
$24,804
$117.63 P/Share
|
|
Dec 12
2025
|
Scott M Davies Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
323
-1.77%
|
$43,928
$136.09 P/Share
|
|
Dec 08
2025
|
Christensen Jakob Wedel SVP, Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
549
-4.77%
|
$70,821
$129.27 P/Share
|
|
Dec 05
2025
|
Christensen Jakob Wedel SVP, Strategy/Corp Development |
SELL
Payment of exercise price or tax liability
|
Direct |
307
-2.6%
|
$39,296
$128.96 P/Share
|
|
Nov 12
2025
|
Scott M Davies Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
323
-1.74%
|
$39,406
$122.79 P/Share
|
|
Nov 05
2025
|
Kevin Carl Pegels Chief of Global Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
599
-2.6%
|
$73,078
$122.44 P/Share
|
|
Nov 05
2025
|
Patricia Leckman SVP, Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
296
-1.5%
|
$36,112
$122.44 P/Share
|
|
Nov 05
2025
|
Scott D Ericksen VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
206
-1.5%
|
$25,132
$122.44 P/Share
|
|
Nov 05
2025
|
Scott M Davies Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
398
-2.1%
|
$48,556
$122.44 P/Share
|
|
Nov 05
2025
|
Steven Barnard SVP, Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
515
-1.54%
|
$62,830
$122.44 P/Share
|
|
Nov 03
2025
|
Scott Gottlieb Director |
BUY
Open market or private purchase
|
Direct |
500
+3.84%
|
$61,000
$122.13 P/Share
|
|
Oct 05
2025
|
Jacob Thaysen Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,301
-1.56%
|
$131,401
$101.02 P/Share
|
|
Sep 30
2025
|
Scott B. Ullem Director |
BUY
Grant, award, or other acquisition
|
Direct |
252
+2.92%
|
$24,948
$99.17 P/Share
|
|
Sep 05
2025
|
Steven Barnard SVP, Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
287
-0.85%
|
$28,126
$98.93 P/Share
|
|
Jul 05
2025
|
Everett Cunningham SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,248
-9.2%
|
$412,056
$97.15 P/Share
|
|
Jun 30
2025
|
Scott B. Ullem Director |
BUY
Grant, award, or other acquisition
|
Direct |
307
+3.64%
|
$24,867
$81.2 P/Share
|
|
May 21
2025
|
Keith A. Meister Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,780
+46.18%
|
-
|
|
May 21
2025
|
Frances Arnold Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,780
+15.31%
|
-
|
|
May 21
2025
|
Philip W Schiller Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,780
+15.8%
|
-
|
|
May 21
2025
|
Anna Richo Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,780
+36.93%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 135K shares |
|---|---|
| Open market or private purchase | 19K shares |
| Sale (or disposition) back to the issuer | 3.21K shares |
|---|---|
| Payment of exercise price or tax liability | 15.8K shares |
| Open market or private sale | 872 shares |